Skip to main content
Loading

Spry Bio, Inc.

October 18, 2023
Franciscan D
Regenerative Medicine
Company Description: Spry Bio, Inc. is a pre-clinical biotechnology company developing Optimized Platelet Therapies (OPTs) for treating osteoarthritis (OA) and other medical conditions characterized by poor vascularization. Spry Bio combines an experienced drug development team with experts in platelet biology, regenerative medicine, and orthopedics. The Company is raising a $3M seed round to develop its first pre-clinical candidate, OPT-OA for treating knee OA, a common and painful condition with few safe and effective treatment options.
Speakers
Terence Russell, CEO - Spry Bio, Inc.